USPTO serial 85683762
MABIMMUNE
Reviewed by CopyMark Law Group
Reg. 4896966Status 710
- Filing date
- Status date
- Registration date
- Feb 9, 2016
- Examiner
- VAGHANI, MAYUR C
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with MABIMMUNE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
SCHLIEREN, CH
Schlieren, CH
Schlieren, CH
Schlieren, CH
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Janice Housey
Janice Housey Litmus LawPO BOX 777BERRYVILLE, VA 22611UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals, namely, chemical preparations containing monoclonal antibodies for biological assays; industrial chemicals containing monoclonal antibodies; chemical preparations containing monoclonal antibodies for scientific purposes; chemical preparations containing monoclonal antibodies for use in photography; biological materials, namely, biological tissue and cell cultures containing monoclonal antibodies other than for medical or veterinary purposes, inoculants in the nature of biological microorganisms containing monoclonal antibodies used for biomedical research; biological preparations, namely, biological tissue and cell cultures containing monoclonal antibodies other than for medical or veterinary purposes, inoculants containing monoclonal antibodies in the nature of biological microorganisms used for biomedical research; peptides for chemicals and foodstuff, namely, peptide substrates containing monoclonal antibodies used in analyzing and detecting certain biomarkers for laboratory or research use; polypeptides, namely, peptide substrates containing monoclonal antibodies used in analyzing and detecting certain biomarkers for laboratory or research use, protein antibodies, namely, monoclonal antibodies containing monoclonal antibodies for in vitro or in-vivo scientific or research use, antibody reagents containing monoclonal antibodies used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; diagnostic preparations containing monoclonal antibodies for scientific use; Biological compounds, namely, epitopes containing monoclonal antibodies in the nature of enzyme or mis-folded proteins for use in the pre-clinical research and development of pharmaceutical preparations such as antibodies or active peptides | SECTION 8 - CANCELLED | — |
| 003 | Skin care preparations containing monoclonal antibodies, namely, chemical peels for skin, anti-aging topical creams, anti-wrinkle topical creams, non-medicated lotions which are indicated specifically for reducing scar formation, topical ointments containing monoclonal antibodies indicated for accelerating the healing process or alleviating the symptoms of burns, namely, non-medicated ointments for the prevention and treatment of sunburn, topical beauty products, namely, cosmetics containing monoclonal antibodies | SECTION 8 - CANCELLED | — |
| 005 | Pharmaceutical preparations containing monoclonal antibodies for keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema, chronic pulmonary disease, cardiomyopathies and a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts; pharmaceutical preparations containing monoclonal antibodies for the treatment of metabolic diseases including diabetes mellitus; veterinary preparations containing monoclonal antibodies for keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema, chronic pulmonary disease, cardiomyopathies and a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts; veterinary preparations containing monoclonal antibodies for metabolic diseases including diabetes mellitus; tumor suppressing agents containing monoclonal antibodies; preparations containing monoclonal antibodies for treating neurodegenerative diseases; immunogenics, namely, pharmaceutical preparations containing monoclonal antibodies for inducing immune responses for the treatment of oncology indications including lymphomas, sarcomas, carcinomas, leukemias, bacterial infections, parasitic disease; vaccines containing monoclonal antibodies; antibodies containing monoclonal antibodies, namely, for treatment of anti-inflammatory, cardiovascular, oncological, and dermatological indications; active epitopes in the form of a pharmaceutical preparation containing monoclonal antibodies which modulate the biological activity of drug targets in-vivo; synthetic peptides containing monoclonal antibodies for pharmaceutical purposes for the treatment of keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema, chronic pulmonary disease, cardiomyopathies and a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts; synthetic peptides for pharmaceutical purposes containing monoclonal antibodies for the treatment of metabolic diseases including diabetes mellitus; sanitary preparations containing monoclonal antibodies for medical purposes; biological preparations for medical purposes containing monoclonal antibodies for the treatment of keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema, chronic pulmonary disease, cardiomyopathies and a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts; biological preparations for medical purposes containing monoclonal antibodies for the treatment of metabolic diseases including diabetes mellitus; biocides containing monoclonal antibodies; diagnostic preparations for medical or veterinary purposes containing monoclonal antibodies; sanitary towels containing monoclonal antibodies; dietetic food, namely, pasta, crackers, bread adapted for medical purposes containing monoclonal antibodies; dietetic beverages, namely, tea, vitamin fortified beverages, protein shakes adapted for medical purposes containing monoclonal antibodies; algaecide chemicals containing monoclonal antibodies for swimming pools; biological tissue containing monoclonal antibodies such as bone, skin, blood vessels, cartilage, muscle, teeth, extracellular matrix, and heart valve tissue intended for subsequent implantation; synthetic peptides and polypeptides containing monoclonal antibodies for the treatment of keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema, chronic pulmonary disease, cardiomyopathies and a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts; synthetic peptides and polypeptides for the treatment of metabolic diseases including diabetes mellitus; chemicals, namely, chemical preparations for pharmaceutical or medical purposes containing monoclonal antibodies, namely, for keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema, chronic pulmonary disease, cardiomyopathies and a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts; pharmaceutical preparations, namely, medicated scar-reducing lotions containing monoclonal antibodies; burn relief medication ointments containing monoclonal antibodies; Chemicals, namely, chemical preparations containing monoclonal antibodies for medical kits and tests, namely, diagnostic blood tests, companion diagnostics, and blood tests to determine the efficacy of the treatment strategy including both plasma and serum based assays for metabolic, cardiovascular, oncological, and inflammatory diseases | SECTION 8 - CANCELLED | — |
| 041 | Physical examination featuring monoclonal antibodies, namely, physical fitness training services, physical performance monitoring in the nature of physical fitness consultation | SECTION 8 - CANCELLED | — |
| 042 | Testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs containing monoclonal antibodies; consultancy and providing information of testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs containing monoclonal antibodies; testing, inspection or research of medical treatment and technique containing monoclonal antibodies; research in the field of biotechnology and antibodies containing monoclonal antibodies; providing information of testing, inspection or research of medical treatment and technique containing monoclonal antibodies; scientific research of health care related to monoclonal antibodies; testing, inspection or research of biology related to monoclonal antibodies; computer software design, computer programming, or maintenance of computer software featuring monoclonal antibodies; computer hardware design and development related to monoclonal antibodies; computer software design and development related to monoclonal antibodies; consultancy and providing information in the field of development of pharmaceutical preparations containing monoclonal antibodies; consultancy and providing information in the field of biomedical research related to monoclonal antibodies | SECTION 8 - CANCELLED | — |
| 044 | Medical services featuring monoclonal antibodies; medical services featuring monoclonal antibodies in the field of immunity, cardiology, rheumatology, oncology, pneumology, neurology; providing medical information featuring monoclonal antibodies; medical services, namely, conducting physical medical examinations featuring monoclonal antibodies in the fields of keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema, chronic pulmonary disease, cardiomyopathies and a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts; medical services featuring monoclonal antibodies, namely, conducting physical medical examinations in the fields of metabolic diseases including diabetes mellitus; preparation and dispensing of medications containing monoclonal antibodies; dietary and nutritional guidance featuring monoclonal antibodies; providing information of health care featuring monoclonal antibodies; consulting in the field of medicine, occupational therapy, and nutrition featuring monoclonal antibodies; veterinary services featuring monoclonal antibodies; beauty salons featuring monoclonal antibodies; animal sanitary services, namely, animal grooming services, animal health care, and veterinary services in the nature of euthanasia of animals featuring monoclonal antibodies; health care featuring monoclonal antibodies; consultancy and providing information in the fields of medical imaging, diagnostic properties of pharmaceuticals, and medical care related to human physiology and pathophysiology featuring monoclonal antibodies; pharmaceutical consultation featuring monoclonal antibodies; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals featuring monoclonal antibodies; physical performance monitoring in the nature of physical therapy or physiotherapy services featuring monoclonal antibodies; ergometry, namely, nutrition counseling featuring monoclonal antibodies; ergometry in the nature of health assessment, namely, blood tests featuring monoclonal antibodies for the evaluation of physical fitness or response to training | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by MABIMMUNE AG
- Other trademarks owned by Mabimmune Diagnostics AG
- Other trademarks owned by Mabimmune Diagnostics AG
- Other trademarks owned by Mabimmune Diagnostics AG
- Other trademarks in Class 001
- Other trademarks in Class 003
- Other trademarks in Class 005
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named MABIMMUNE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 19, 2022 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Jul 21, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 21, 2021 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Jul 21, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 21, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 9, 2021 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| May 13, 2020 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Mar 10, 2016 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 9, 2016 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 24, 2015 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 24, 2015 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 4, 2015 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 16, 2015 | RPUB | NOA CANCELLED; REPUBLICATION REQUIRED | — |
| Oct 16, 2015 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Oct 15, 2015 | PCBG | PETITION TO DIRECTOR - CHANGE BASIS - GRANTED | — |
| Oct 14, 2015 | APET | ASSIGNED TO PETITION STAFF | — |
| Oct 9, 2015 | TPAD | TEAS PETITION TO AMEND BASIS RECEIVED | — |
| Aug 27, 2015 | CORV | REVIEW OF CORRESPONDENCE COMPLETE | — |
| Apr 23, 2015 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 21, 2015 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Apr 21, 2015 | EXT1 | SOU EXTENSION 1 FILED | — |
| Apr 21, 2015 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 15, 2015 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Nov 19, 2014 | D1BR | TEAS DELETE 1(B) BASIS RECEIVED | — |
| Oct 28, 2014 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 2, 2014 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 2, 2014 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 13, 2014 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 31, 2014 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jul 28, 2014 | EXPT | EXPARTE APPEAL TERMINATED | — |
| Jul 28, 2014 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 24, 2014 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 23, 2014 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 23, 2014 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 6, 2014 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 6, 2014 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 6, 2014 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 27, 2014 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Feb 10, 2014 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Jan 25, 2014 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jan 23, 2014 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 23, 2014 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 23, 2014 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 23, 2014 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 23, 2014 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 6, 2014 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 6, 2014 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 30, 2013 | ALIE | ASSIGNED TO LIE | — |
| Dec 6, 2013 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Dec 6, 2013 | EXPI | EX PARTE APPEAL-INSTITUTED | — |
| Dec 6, 2013 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Dec 6, 2013 | EXAF | EXPARTE APPEAL RECEIVED AT TTAB | — |
| Jun 6, 2013 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jun 6, 2013 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 6, 2013 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 16, 2013 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 15, 2013 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 15, 2013 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 16, 2012 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 16, 2012 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 16, 2012 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 15, 2012 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 13, 2012 | TAEA | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED | — |
| Aug 13, 2012 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Jul 27, 2012 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 25, 2012 | NWAP | NEW APPLICATION ENTERED | — |